Mark H. L. Lambermon

Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis

JoAnne McLaurin, Roxana Cecal, Meredith E. Kierstead et al. · Nature Medicine · 2002 · 411 citations

Alzheimer's Disease, Medicine, Peptide Engineering +9

Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model

JoAnne McLaurin, Meredith E. Kierstead, Mary E. Brown et al. · Nature Medicine · 2006 · 361 citations

Molecular Pharmacology, Neurodegenerative Diseases, Alzheimer's Disease +13

UBP1, a novel hnRNP-like protein that functions at multiple steps of higher plant nuclear pre-mRNA maturation

Mark H. L. Lambermon · The EMBO Journal · 2000 · 110 citations · Full text

Plant Molecular Biology, Developmental Biology, Genetics +7

SRm160 Splicing Coactivator Promotes Transcript 3′-End Cleavage

Susan McCracken, Mark H. L. Lambermon, Benjamin J. Blencowe · Molecular and Cellular Biology · 2002 · 102 citations · Full text

Site-Specific Modification of <i>Candida antarctica</i> Lipase B via Residue-Specific Incorporation of a Non-Canonical Amino Acid

Sanne Schoffelen, Mark H. L. Lambermon, Mark B. van Eldijk et al. · Bioconjugate Chemistry · 2008 · 84 citations

Bioorganic Chemistry, Engineering, Solvent-exposed Methionine +19